Congresswoman Claudia Tenney has reintroduced the Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. This legislation aims to encourage domestic production of generic medicines in the United States. The move comes amid concerns about the centralization of drug manufacturing in India and China, which are known for lower costs and less stringent manufacturing standards.
The PILLS Act proposes tax incentives for pharmaceutical companies to relocate all stages of generic medicine production, including materials and testing, back to the U.S. Congresswoman Tenney stated, “Drug manufacturing has moved overseas, putting American jobs and the security of our essential medical supply chains at risk. To address this, I reintroduced the PILLS Act, which incentivizes businesses to produce critical generic medications and antibiotics here in the U.S.”
Zach Mottl, Chairman of the Coalition for a Prosperous America (CPA), supports the bill. He said, “Congresswoman Tenney’s PILLS Act is a critical step toward reshoring America’s generic drug production and reducing our dangerous dependence on foreign suppliers.” He highlighted that over 90% of prescriptions dispensed in the U.S. are generic drugs and noted significant increases in imports from India and China since 2002.
David Sanders, Founder and Board Member of Securing America’s Medicines and Supply (SAMS) and Vice President of Coherus BioSciences, also endorsed the act. He expressed gratitude towards Representative Tenney’s leadership on this issue: “Thank you, Representative Tenney, for your leadership on the PILLS Act… Equally important, the PILLS Act will create more American jobs, reduce our Nation’s overreliance on foreign production, and improve patient access to essential medicines.”
